Dean J. Naylor

Corporate Officer/Principal bei The University of Queensland

Consumer Services

Health Technology

Profil

Dean J.
Naylor is currently a Principal at The University of Queensland.
Prior to this, he was a Principal at the University of Adelaide and Head-Intellectual Property Development at CBio Ltd.

Aktive Positionen von Dean J. Naylor

Unternehmen	Position	Beginn
The University of Queensland	Corporate Officer/Principal	-

Alle aktiven Positionen von Dean J. Naylor

Ehemalige bekannte Positionen von Dean J. Naylor

Unternehmen	Position	Ende
University of Adelaide	Corporate Officer/Principal	-
CBio Ltd. CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Dean J. Naylor im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Dean J. Naylor im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	1
CBio Ltd. CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.	Health Technology